Jason Farrar
Concepts (506)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Myeloid, Acute | 15 | 2024 | 203 | 3.070 |
Why?
| | Anemia, Diamond-Blackfan | 13 | 2024 | 13 | 2.720 |
Why?
| | Mutation | 19 | 2023 | 1347 | 1.850 |
Why?
| | Ribosomal Proteins | 9 | 2021 | 24 | 1.480 |
Why?
| | Venous Thromboembolism | 2 | 2021 | 77 | 1.340 |
Why?
| | Critical Illness | 7 | 2025 | 317 | 1.150 |
Why?
| | Public Health | 5 | 2025 | 223 | 1.120 |
Why?
| | Wounds and Injuries | 4 | 2025 | 309 | 1.070 |
Why?
| | Humans | 103 | 2025 | 52483 | 0.910 |
Why?
| | Midazolam | 1 | 2024 | 37 | 0.910 |
Why?
| | Biomedical Research | 3 | 2025 | 256 | 0.900 |
Why?
| | Pneumonia, Ventilator-Associated | 2 | 2025 | 22 | 0.890 |
Why?
| | Hypnotics and Sedatives | 1 | 2024 | 72 | 0.870 |
Why?
| | Anti-Infective Agents | 2 | 2022 | 107 | 0.850 |
Why?
| | Neurosurgical Procedures | 1 | 2024 | 135 | 0.820 |
Why?
| | Gene Expression Profiling | 7 | 2023 | 1105 | 0.800 |
Why?
| | Body Weight | 2 | 2021 | 523 | 0.770 |
Why?
| | Rhabdomyosarcoma, Alveolar | 1 | 2021 | 8 | 0.750 |
Why?
| | Li-Fraumeni Syndrome | 1 | 2021 | 12 | 0.750 |
Why?
| | Enoxaparin | 1 | 2021 | 31 | 0.710 |
Why?
| | Anti-Bacterial Agents | 6 | 2025 | 807 | 0.710 |
Why?
| | Vietnam | 22 | 2020 | 44 | 0.690 |
Why?
| | Stenotrophomonas maltophilia | 1 | 2020 | 7 | 0.680 |
Why?
| | Gram-Negative Bacterial Infections | 1 | 2020 | 44 | 0.660 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2021 | 221 | 0.650 |
Why?
| | Influenza, Human | 6 | 2018 | 93 | 0.620 |
Why?
| | Anticoagulants | 1 | 2021 | 270 | 0.590 |
Why?
| | Thrombosis | 1 | 2021 | 253 | 0.590 |
Why?
| | Dengue | 5 | 2016 | 7 | 0.550 |
Why?
| | RNA Processing, Post-Transcriptional | 3 | 2014 | 24 | 0.540 |
Why?
| | Child, Preschool | 23 | 2021 | 4076 | 0.540 |
Why?
| | Female | 36 | 2025 | 28171 | 0.530 |
Why?
| | Male | 35 | 2025 | 26761 | 0.520 |
Why?
| | Adult | 24 | 2025 | 14161 | 0.510 |
Why?
| | Epidemics | 4 | 2022 | 25 | 0.490 |
Why?
| | GATA1 Transcription Factor | 2 | 2017 | 7 | 0.480 |
Why?
| | Child | 30 | 2025 | 7248 | 0.480 |
Why?
| | Oncogene Proteins, Fusion | 4 | 2024 | 61 | 0.470 |
Why?
| | RNA, Ribosomal | 1 | 2014 | 18 | 0.460 |
Why?
| | RNA Precursors | 1 | 2014 | 9 | 0.460 |
Why?
| | Intensive Care Units | 4 | 2025 | 243 | 0.450 |
Why?
| | Infant | 18 | 2021 | 3733 | 0.450 |
Why?
| | Codon, Initiator | 1 | 2014 | 9 | 0.450 |
Why?
| | Malaria, Falciparum | 3 | 2020 | 23 | 0.440 |
Why?
| | Meningitis, Cryptococcal | 2 | 2010 | 10 | 0.440 |
Why?
| | Typhoid Fever | 4 | 2015 | 5 | 0.440 |
Why?
| | Point Mutation | 1 | 2014 | 67 | 0.440 |
Why?
| | Enteral Nutrition | 2 | 2025 | 154 | 0.420 |
Why?
| | Aged | 13 | 2025 | 10121 | 0.410 |
Why?
| | Vaccination | 6 | 2024 | 298 | 0.410 |
Why?
| | Middle Aged | 16 | 2025 | 13028 | 0.400 |
Why?
| | Breast Neoplasms | 1 | 2021 | 1212 | 0.390 |
Why?
| | Science | 3 | 2021 | 20 | 0.390 |
Why?
| | Prognosis | 6 | 2024 | 2099 | 0.370 |
Why?
| | Cryptococcus neoformans | 2 | 2010 | 26 | 0.370 |
Why?
| | Drug Resistance, Multiple, Bacterial | 4 | 2025 | 70 | 0.360 |
Why?
| | Artemisinins | 3 | 2020 | 8 | 0.360 |
Why?
| | Amplified Fragment Length Polymorphism Analysis | 1 | 2010 | 3 | 0.360 |
Why?
| | Mycological Typing Techniques | 1 | 2010 | 3 | 0.360 |
Why?
| | Mycobacterium tuberculosis | 4 | 2018 | 291 | 0.350 |
Why?
| | Antimalarials | 3 | 2020 | 32 | 0.350 |
Why?
| | DNA, Fungal | 1 | 2010 | 43 | 0.350 |
Why?
| | Gene Deletion | 1 | 2011 | 272 | 0.340 |
Why?
| | Disease Outbreaks | 5 | 2022 | 123 | 0.340 |
Why?
| | Adolescent | 19 | 2025 | 6739 | 0.340 |
Why?
| | Evolution, Molecular | 3 | 2021 | 93 | 0.330 |
Why?
| | Antibodies, Viral | 5 | 2021 | 109 | 0.330 |
Why?
| | Salmonella typhi | 3 | 2015 | 5 | 0.320 |
Why?
| | Viruses | 3 | 2015 | 25 | 0.310 |
Why?
| | Malaria | 2 | 2020 | 42 | 0.310 |
Why?
| | Insulin, Isophane | 2 | 2025 | 2 | 0.310 |
Why?
| | Viral Vaccines | 2 | 2020 | 16 | 0.300 |
Why?
| | Young Adult | 15 | 2025 | 4329 | 0.300 |
Why?
| | Hyperglycemia | 2 | 2025 | 88 | 0.290 |
Why?
| | Influenza A Virus, H5N1 Subtype | 4 | 2016 | 7 | 0.290 |
Why?
| | Dengue Vaccines | 2 | 2018 | 2 | 0.280 |
Why?
| | Hand, Foot and Mouth Disease | 2 | 2018 | 2 | 0.280 |
Why?
| | Enterovirus | 2 | 2018 | 8 | 0.280 |
Why?
| | Retrospective Studies | 7 | 2025 | 6607 | 0.280 |
Why?
| | Polymorphism, Single Nucleotide | 5 | 2018 | 505 | 0.270 |
Why?
| | Information Dissemination | 2 | 2020 | 84 | 0.270 |
Why?
| | DNA Methylation | 6 | 2023 | 592 | 0.270 |
Why?
| | Pneumonia, Viral | 2 | 2020 | 178 | 0.270 |
Why?
| | Dengue Virus | 2 | 2018 | 13 | 0.270 |
Why?
| | Coronavirus Infections | 2 | 2020 | 188 | 0.260 |
Why?
| | Hypoglycemic Agents | 2 | 2025 | 211 | 0.260 |
Why?
| | Prospective Studies | 6 | 2024 | 2481 | 0.250 |
Why?
| | Respiratory Syncytial Virus Infections | 2 | 2016 | 42 | 0.250 |
Why?
| | Communicable Diseases, Emerging | 2 | 2015 | 13 | 0.250 |
Why?
| | Exocrine Pancreatic Insufficiency | 1 | 2025 | 4 | 0.240 |
Why?
| | Lipomatosis | 1 | 2025 | 6 | 0.240 |
Why?
| | Incidence | 4 | 2025 | 1062 | 0.240 |
Why?
| | Viral Load | 3 | 2021 | 82 | 0.240 |
Why?
| | Bone Marrow Diseases | 1 | 2025 | 11 | 0.240 |
Why?
| | Kidney Function Tests | 1 | 2025 | 54 | 0.240 |
Why?
| | Blood Glucose | 2 | 2025 | 473 | 0.240 |
Why?
| | Oligonucleotide Array Sequence Analysis | 3 | 2011 | 405 | 0.240 |
Why?
| | Enterovirus Infections | 2 | 2015 | 7 | 0.230 |
Why?
| | Swine Diseases | 2 | 2015 | 7 | 0.230 |
Why?
| | Creatinine | 1 | 2025 | 150 | 0.230 |
Why?
| | Nutritional Support | 1 | 2024 | 35 | 0.230 |
Why?
| | Tuberculosis | 2 | 2018 | 152 | 0.230 |
Why?
| | Respiratory Tract Infections | 2 | 2016 | 87 | 0.230 |
Why?
| | Lymphoma | 1 | 2025 | 71 | 0.230 |
Why?
| | Central Nervous System Infections | 2 | 2014 | 7 | 0.220 |
Why?
| | Hemophilia A | 1 | 2024 | 26 | 0.220 |
Why?
| | Adaptive Immunity | 2 | 2021 | 34 | 0.220 |
Why?
| | Drug Incompatibility | 1 | 2023 | 2 | 0.210 |
Why?
| | Hemorrhage | 2 | 2024 | 209 | 0.210 |
Why?
| | Genotype | 6 | 2018 | 566 | 0.210 |
Why?
| | Neuromuscular Blockade | 1 | 2023 | 14 | 0.210 |
Why?
| | Gene Rearrangement | 1 | 2024 | 75 | 0.210 |
Why?
| | Cell Cycle Proteins | 2 | 2021 | 169 | 0.210 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2024 | 339 | 0.210 |
Why?
| | Consensus | 1 | 2024 | 181 | 0.210 |
Why?
| | Osteosarcoma | 1 | 2023 | 44 | 0.200 |
Why?
| | Tandem Mass Spectrometry | 1 | 2024 | 251 | 0.200 |
Why?
| | Tuberculosis, Pulmonary | 2 | 2018 | 111 | 0.200 |
Why?
| | World Health Organization | 4 | 2018 | 59 | 0.200 |
Why?
| | Infection Control | 2 | 2019 | 47 | 0.200 |
Why?
| | Tuberculosis, Meningeal | 2 | 2016 | 5 | 0.200 |
Why?
| | Genetic Variation | 5 | 2015 | 230 | 0.200 |
Why?
| | Risk Factors | 6 | 2025 | 3889 | 0.200 |
Why?
| | Chromosome Aberrations | 3 | 2017 | 297 | 0.190 |
Why?
| | Azacitidine | 2 | 2023 | 39 | 0.190 |
Why?
| | Leukemia, Myelomonocytic, Juvenile | 1 | 2022 | 15 | 0.190 |
Why?
| | Serum Albumin | 1 | 2022 | 58 | 0.190 |
Why?
| | Recurrence | 3 | 2022 | 672 | 0.190 |
Why?
| | Vaccines, Attenuated | 2 | 2018 | 11 | 0.180 |
Why?
| | Renal Replacement Therapy | 1 | 2022 | 34 | 0.180 |
Why?
| | Biotechnology | 1 | 2021 | 15 | 0.180 |
Why?
| | Myelitis | 1 | 2021 | 1 | 0.180 |
Why?
| | Enterovirus D, Human | 1 | 2021 | 1 | 0.180 |
Why?
| | Drug Dosage Calculations | 1 | 2021 | 11 | 0.180 |
Why?
| | Central Nervous System Viral Diseases | 1 | 2021 | 2 | 0.180 |
Why?
| | Age Factors | 3 | 2021 | 1132 | 0.180 |
Why?
| | Bone Neoplasms | 1 | 2023 | 184 | 0.180 |
Why?
| | Plasmodium falciparum | 2 | 2020 | 26 | 0.180 |
Why?
| | Narration | 1 | 2021 | 28 | 0.180 |
Why?
| | Co-Repressor Proteins | 1 | 2021 | 18 | 0.180 |
Why?
| | Neoplasms, Second Primary | 1 | 2022 | 77 | 0.180 |
Why?
| | Erythrocyte Transfusion | 1 | 2021 | 52 | 0.180 |
Why?
| | Gene Regulatory Networks | 1 | 2021 | 111 | 0.180 |
Why?
| | Chromosomal Proteins, Non-Histone | 1 | 2021 | 36 | 0.180 |
Why?
| | Diabetes Mellitus | 1 | 2024 | 316 | 0.180 |
Why?
| | Neuromuscular Diseases | 1 | 2021 | 31 | 0.170 |
Why?
| | Injury Severity Score | 1 | 2021 | 167 | 0.170 |
Why?
| | B-Lymphocytes | 1 | 2021 | 184 | 0.170 |
Why?
| | Leadership | 1 | 2021 | 103 | 0.170 |
Why?
| | Kidney | 1 | 2025 | 707 | 0.170 |
Why?
| | Chromatin | 1 | 2021 | 139 | 0.170 |
Why?
| | Leucine | 1 | 2020 | 114 | 0.170 |
Why?
| | Microbial Sensitivity Tests | 4 | 2015 | 284 | 0.170 |
Why?
| | International Cooperation | 2 | 2017 | 49 | 0.160 |
Why?
| | Bacteremia | 1 | 2020 | 92 | 0.160 |
Why?
| | Blood Transfusion | 1 | 2020 | 127 | 0.160 |
Why?
| | Molecular Sequence Data | 5 | 2015 | 778 | 0.160 |
Why?
| | Respiratory Syncytial Virus, Human | 2 | 2016 | 15 | 0.160 |
Why?
| | MicroRNAs | 2 | 2021 | 387 | 0.160 |
Why?
| | Hemorrhagic Fever, Ebola | 2 | 2015 | 7 | 0.150 |
Why?
| | Ribosomes | 2 | 2009 | 33 | 0.150 |
Why?
| | Orthomyxoviridae | 1 | 2018 | 4 | 0.150 |
Why?
| | Sex Factors | 1 | 2021 | 727 | 0.150 |
Why?
| | Plasmodium | 1 | 2018 | 5 | 0.150 |
Why?
| | Immunization, Secondary | 1 | 2018 | 24 | 0.150 |
Why?
| | Mosquito Control | 1 | 2018 | 6 | 0.150 |
Why?
| | Research Report | 1 | 2018 | 16 | 0.150 |
Why?
| | Base Sequence | 5 | 2014 | 640 | 0.150 |
Why?
| | Infant, Newborn | 5 | 2023 | 2867 | 0.150 |
Why?
| | Influenza in Birds | 2 | 2016 | 6 | 0.150 |
Why?
| | Genome, Viral | 2 | 2015 | 83 | 0.150 |
Why?
| | DNA-Binding Proteins | 1 | 2021 | 422 | 0.150 |
Why?
| | Isoniazid | 1 | 2018 | 36 | 0.150 |
Why?
| | Tuberculosis, Multidrug-Resistant | 1 | 2018 | 42 | 0.140 |
Why?
| | Treatment Outcome | 4 | 2023 | 5422 | 0.140 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2021 | 1378 | 0.140 |
Why?
| | Influenza A virus | 1 | 2017 | 20 | 0.140 |
Why?
| | Antitubercular Agents | 1 | 2018 | 107 | 0.140 |
Why?
| | Induction Chemotherapy | 1 | 2017 | 64 | 0.140 |
Why?
| | Parasitemia | 1 | 2017 | 10 | 0.140 |
Why?
| | Malaria, Cerebral | 1 | 2017 | 1 | 0.140 |
Why?
| | Glucosephosphate Dehydrogenase Deficiency | 1 | 2017 | 4 | 0.140 |
Why?
| | Endemic Diseases | 1 | 2017 | 25 | 0.140 |
Why?
| | Ribosome Subunits, Large, Eukaryotic | 2 | 2014 | 2 | 0.140 |
Why?
| | Agammaglobulinemia | 1 | 1996 | 9 | 0.130 |
Why?
| | X Chromosome | 1 | 1996 | 13 | 0.130 |
Why?
| | Protozoan Proteins | 1 | 2017 | 32 | 0.130 |
Why?
| | Genome, Human | 2 | 2021 | 121 | 0.130 |
Why?
| | Public Health Practice | 1 | 2017 | 42 | 0.130 |
Why?
| | Reverse Transcriptase Inhibitors | 1 | 2016 | 8 | 0.130 |
Why?
| | Severity of Illness Index | 5 | 2024 | 1026 | 0.130 |
Why?
| | Benzoxazines | 1 | 2016 | 18 | 0.130 |
Why?
| | Receptors, Colony-Stimulating Factor | 1 | 2016 | 1 | 0.130 |
Why?
| | Phenotype | 3 | 2021 | 789 | 0.130 |
Why?
| | Disease Susceptibility | 3 | 2021 | 95 | 0.130 |
Why?
| | CCAAT-Enhancer-Binding Proteins | 1 | 2016 | 14 | 0.130 |
Why?
| | Enterovirus A, Human | 1 | 2016 | 1 | 0.130 |
Why?
| | Anemia | 1 | 2017 | 74 | 0.130 |
Why?
| | HIV Infections | 2 | 2010 | 389 | 0.130 |
Why?
| | Cell Proliferation | 4 | 2021 | 1023 | 0.130 |
Why?
| | Animals | 13 | 2023 | 13505 | 0.130 |
Why?
| | Neutropenia | 1 | 1996 | 115 | 0.130 |
Why?
| | Kobuvirus | 1 | 2015 | 2 | 0.130 |
Why?
| | Immunologic Factors | 2 | 2013 | 117 | 0.130 |
Why?
| | Ebola Vaccines | 1 | 2015 | 1 | 0.130 |
Why?
| | Public-Private Sector Partnerships | 1 | 2015 | 8 | 0.120 |
Why?
| | Reagent Kits, Diagnostic | 2 | 2013 | 17 | 0.120 |
Why?
| | Editorial Policies | 1 | 2015 | 12 | 0.120 |
Why?
| | Models, Theoretical | 3 | 2021 | 185 | 0.120 |
Why?
| | Animals, Wild | 1 | 2015 | 10 | 0.120 |
Why?
| | Case-Control Studies | 4 | 2017 | 1201 | 0.120 |
Why?
| | Zoonoses | 1 | 2015 | 13 | 0.120 |
Why?
| | Picornaviridae Infections | 1 | 2015 | 22 | 0.120 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 3 | 2011 | 582 | 0.120 |
Why?
| | DNA Copy Number Variations | 1 | 2016 | 117 | 0.120 |
Why?
| | Hepatitis E | 1 | 2015 | 6 | 0.120 |
Why?
| | Earthquakes | 1 | 2015 | 5 | 0.120 |
Why?
| | Emergencies | 1 | 2015 | 81 | 0.120 |
Why?
| | Biomedical Technology | 1 | 2015 | 10 | 0.120 |
Why?
| | Azithromycin | 1 | 2015 | 26 | 0.120 |
Why?
| | Salmonella enterica | 1 | 2015 | 17 | 0.120 |
Why?
| | DNA, Bacterial | 2 | 2018 | 176 | 0.120 |
Why?
| | Epidemiological Monitoring | 3 | 2021 | 14 | 0.120 |
Why?
| | Feces | 1 | 2015 | 153 | 0.120 |
Why?
| | Research Support as Topic | 1 | 2015 | 44 | 0.120 |
Why?
| | Periodicals as Topic | 1 | 2015 | 61 | 0.120 |
Why?
| | Health Care Costs | 1 | 2016 | 174 | 0.120 |
Why?
| | Viral Envelope Proteins | 1 | 2014 | 35 | 0.120 |
Why?
| | Registries | 1 | 2018 | 581 | 0.120 |
Why?
| | Encephalitis, Viral | 2 | 2013 | 7 | 0.120 |
Why?
| | Ribosome Subunits, Small, Eukaryotic | 1 | 2014 | 2 | 0.110 |
Why?
| | K562 Cells | 1 | 2014 | 42 | 0.110 |
Why?
| | Transcription Factors | 3 | 2024 | 566 | 0.110 |
Why?
| | Health Policy | 1 | 2015 | 158 | 0.110 |
Why?
| | Virus Diseases | 1 | 2015 | 46 | 0.110 |
Why?
| | Antibodies, Neutralizing | 1 | 2014 | 78 | 0.110 |
Why?
| | Chromosome Mapping | 3 | 2011 | 154 | 0.110 |
Why?
| | Circoviridae | 1 | 2014 | 1 | 0.110 |
Why?
| | Circoviridae Infections | 1 | 2014 | 1 | 0.110 |
Why?
| | Leukemia, Myeloid | 1 | 2014 | 42 | 0.110 |
Why?
| | Tertiary Care Centers | 1 | 2014 | 85 | 0.110 |
Why?
| | Enteroviruses, Porcine | 1 | 2013 | 1 | 0.110 |
Why?
| | Health Services Needs and Demand | 1 | 2015 | 159 | 0.110 |
Why?
| | Molecular Epidemiology | 2 | 2010 | 38 | 0.110 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2015 | 81 | 0.110 |
Why?
| | Anemia, Macrocytic | 1 | 2013 | 2 | 0.110 |
Why?
| | Prednisolone | 1 | 2013 | 56 | 0.110 |
Why?
| | Cluster Analysis | 2 | 2010 | 233 | 0.100 |
Why?
| | Cytogenetic Analysis | 1 | 2013 | 80 | 0.100 |
Why?
| | Recombination, Genetic | 1 | 2013 | 109 | 0.100 |
Why?
| | Cohort Studies | 3 | 2018 | 1542 | 0.100 |
Why?
| | Bacteriological Techniques | 1 | 2013 | 42 | 0.100 |
Why?
| | China | 3 | 2020 | 134 | 0.100 |
Why?
| | Phylogeny | 4 | 2015 | 231 | 0.100 |
Why?
| | Models, Biological | 2 | 2021 | 735 | 0.100 |
Why?
| | Genomics | 1 | 2014 | 268 | 0.100 |
Why?
| | Advisory Committees | 2 | 2015 | 71 | 0.100 |
Why?
| | RNA, Messenger | 4 | 2021 | 1132 | 0.100 |
Why?
| | Nervous System Diseases | 1 | 2013 | 95 | 0.100 |
Why?
| | Amino Acid Sequence | 2 | 2015 | 578 | 0.100 |
Why?
| | Heart Defects, Congenital | 1 | 2018 | 619 | 0.100 |
Why?
| | Chromosome Deletion | 2 | 2013 | 142 | 0.090 |
Why?
| | Haploinsufficiency | 1 | 2011 | 15 | 0.090 |
Why?
| | Mosaicism | 1 | 2011 | 17 | 0.090 |
Why?
| | Genotyping Techniques | 1 | 2011 | 21 | 0.090 |
Why?
| | Blotting, Northern | 1 | 2011 | 106 | 0.090 |
Why?
| | Immune Evasion | 2 | 2021 | 15 | 0.090 |
Why?
| | Prevalence | 4 | 2018 | 1006 | 0.090 |
Why?
| | RNA, Small Interfering | 2 | 2008 | 213 | 0.090 |
Why?
| | Neoplastic Stem Cells | 2 | 2022 | 99 | 0.090 |
Why?
| | Pilot Projects | 2 | 2025 | 721 | 0.090 |
Why?
| | Genome-Wide Association Study | 1 | 2011 | 186 | 0.090 |
Why?
| | Viremia | 1 | 2010 | 23 | 0.080 |
Why?
| | Bacterial Typing Techniques | 1 | 2010 | 36 | 0.080 |
Why?
| | Cell Line | 2 | 2014 | 1030 | 0.080 |
Why?
| | Daunorubicin | 2 | 2022 | 13 | 0.080 |
Why?
| | WT1 Proteins | 1 | 2009 | 4 | 0.080 |
Why?
| | Cytarabine | 2 | 2022 | 42 | 0.080 |
Why?
| | Enterobacteriaceae | 1 | 2009 | 8 | 0.080 |
Why?
| | Outpatients | 2 | 2024 | 125 | 0.080 |
Why?
| | Viral Nonstructural Proteins | 1 | 2010 | 61 | 0.080 |
Why?
| | Enterobacteriaceae Infections | 1 | 2009 | 18 | 0.080 |
Why?
| | Plasmids | 1 | 2009 | 163 | 0.080 |
Why?
| | Quinolones | 1 | 2009 | 50 | 0.080 |
Why?
| | Semliki forest virus | 1 | 2008 | 1 | 0.080 |
Why?
| | Chromosomes, Human, Pair 3 | 1 | 2008 | 19 | 0.070 |
Why?
| | Seasons | 2 | 2020 | 92 | 0.070 |
Why?
| | Saccharomyces cerevisiae Proteins | 1 | 2009 | 139 | 0.070 |
Why?
| | Pedigree | 1 | 2008 | 125 | 0.070 |
Why?
| | Seroepidemiologic Studies | 2 | 2018 | 44 | 0.070 |
Why?
| | DNA, Viral | 3 | 2015 | 137 | 0.070 |
Why?
| | Pandemics | 2 | 2024 | 585 | 0.070 |
Why?
| | Chromosomes, Human, Pair 6 | 1 | 2007 | 15 | 0.070 |
Why?
| | Wilms Tumor | 1 | 2007 | 19 | 0.070 |
Why?
| | Genes, Tumor Suppressor | 1 | 2007 | 74 | 0.070 |
Why?
| | Neuraminidase | 1 | 2007 | 4 | 0.070 |
Why?
| | Oseltamivir | 1 | 2007 | 5 | 0.070 |
Why?
| | Receptors, Interleukin-1 | 1 | 2006 | 18 | 0.070 |
Why?
| | Genetic Predisposition to Disease | 2 | 2007 | 528 | 0.070 |
Why?
| | Ubiquitin-Protein Ligases | 1 | 2007 | 96 | 0.070 |
Why?
| | Toll-Like Receptors | 1 | 2006 | 27 | 0.070 |
Why?
| | DNA Helicases | 1 | 2008 | 150 | 0.070 |
Why?
| | Cell Differentiation | 2 | 2021 | 665 | 0.060 |
Why?
| | Mice | 4 | 2023 | 5949 | 0.060 |
Why?
| | Alleles | 2 | 2017 | 276 | 0.060 |
Why?
| | Quinolines | 2 | 2017 | 44 | 0.060 |
Why?
| | Treatment Failure | 2 | 2018 | 122 | 0.060 |
Why?
| | Kidney Neoplasms | 1 | 2007 | 182 | 0.060 |
Why?
| | Rifampin | 2 | 2018 | 63 | 0.060 |
Why?
| | Antiviral Agents | 1 | 2007 | 178 | 0.060 |
Why?
| | Graft vs Host Disease | 1 | 2005 | 87 | 0.060 |
Why?
| | Tacrolimus | 1 | 2005 | 59 | 0.060 |
Why?
| | Sus scrofa | 2 | 2015 | 39 | 0.060 |
Why?
| | Glomerular Filtration Rate | 1 | 2025 | 124 | 0.060 |
Why?
| | Hypoglycemia | 1 | 2025 | 59 | 0.060 |
Why?
| | DNA | 1 | 2008 | 549 | 0.060 |
Why?
| | Drug Administration Schedule | 1 | 2025 | 374 | 0.060 |
Why?
| | Autoimmune Diseases | 1 | 2005 | 86 | 0.060 |
Why?
| | Follow-Up Studies | 2 | 2020 | 2279 | 0.060 |
Why?
| | Transcriptome | 2 | 2017 | 370 | 0.060 |
Why?
| | Nucleosome Assembly Protein 1 | 1 | 2024 | 1 | 0.060 |
Why?
| | Minor Histocompatibility Antigens | 1 | 2024 | 18 | 0.060 |
Why?
| | Factor VIII | 1 | 2024 | 23 | 0.060 |
Why?
| | Myeloid-Lymphoid Leukemia Protein | 1 | 2024 | 14 | 0.050 |
Why?
| | Proto-Oncogenes | 1 | 2024 | 27 | 0.050 |
Why?
| | Mass Screening | 2 | 2018 | 357 | 0.050 |
Why?
| | DEAD-box RNA Helicases | 1 | 2024 | 34 | 0.050 |
Why?
| | Practice Guidelines as Topic | 1 | 2007 | 488 | 0.050 |
Why?
| | Haplotypes | 2 | 2017 | 92 | 0.050 |
Why?
| | Retinoblastoma-Binding Protein 2 | 1 | 2023 | 6 | 0.050 |
Why?
| | Sequence Analysis, DNA | 2 | 2015 | 229 | 0.050 |
Why?
| | Nuclear Pore Complex Proteins | 1 | 2023 | 10 | 0.050 |
Why?
| | Real-Time Polymerase Chain Reaction | 2 | 2015 | 185 | 0.050 |
Why?
| | Proto-Oncogene Proteins c-ret | 1 | 2024 | 33 | 0.050 |
Why?
| | Uncertainty | 1 | 2023 | 44 | 0.050 |
Why?
| | Swine | 2 | 2015 | 428 | 0.050 |
Why?
| | Autoantibodies | 1 | 2024 | 121 | 0.050 |
Why?
| | Trauma Centers | 1 | 2025 | 209 | 0.050 |
Why?
| | Viral Proteins | 2 | 2015 | 164 | 0.050 |
Why?
| | Nepal | 2 | 2015 | 12 | 0.050 |
Why?
| | Time Factors | 2 | 2020 | 2968 | 0.050 |
Why?
| | CpG Islands | 1 | 2023 | 121 | 0.050 |
Why?
| | Ambulatory Care | 1 | 2024 | 239 | 0.050 |
Why?
| | Apoptosis | 1 | 2008 | 1119 | 0.050 |
Why?
| | Computational Biology | 1 | 2024 | 212 | 0.050 |
Why?
| | Disease Management | 1 | 2024 | 188 | 0.050 |
Why?
| | Pharmaceutical Preparations | 1 | 2023 | 77 | 0.050 |
Why?
| | Predictive Value of Tests | 1 | 2025 | 944 | 0.050 |
Why?
| | Point-of-Care Systems | 2 | 2015 | 65 | 0.050 |
Why?
| | Poultry | 2 | 2016 | 29 | 0.050 |
Why?
| | Insulin | 1 | 2024 | 479 | 0.050 |
Why?
| | Proto-Oncogene Proteins c-cbl | 1 | 2022 | 3 | 0.050 |
Why?
| | Core Binding Factor beta Subunit | 1 | 2021 | 4 | 0.050 |
Why?
| | Myosin Heavy Chains | 1 | 2021 | 25 | 0.050 |
Why?
| | Strategic Stockpile | 1 | 2021 | 1 | 0.050 |
Why?
| | Emigration and Immigration | 1 | 2021 | 18 | 0.050 |
Why?
| | RNA | 1 | 2022 | 168 | 0.050 |
Why?
| | Spatio-Temporal Analysis | 1 | 2021 | 11 | 0.050 |
Why?
| | Risk Assessment | 2 | 2017 | 1327 | 0.050 |
Why?
| | Drug Resistance, Bacterial | 2 | 2013 | 82 | 0.040 |
Why?
| | Immunization Schedule | 1 | 2021 | 11 | 0.040 |
Why?
| | Selection, Genetic | 1 | 2021 | 28 | 0.040 |
Why?
| | Gene Expression Regulation, Leukemic | 1 | 2021 | 32 | 0.040 |
Why?
| | Africa | 1 | 2020 | 12 | 0.040 |
Why?
| | Disease Models, Animal | 2 | 2021 | 1478 | 0.040 |
Why?
| | Acetylation | 1 | 2021 | 95 | 0.040 |
Why?
| | Chronic Disease | 1 | 2023 | 586 | 0.040 |
Why?
| | Enhancer Elements, Genetic | 1 | 2021 | 58 | 0.040 |
Why?
| | Antibody-Dependent Enhancement | 1 | 2020 | 2 | 0.040 |
Why?
| | Cross Reactions | 1 | 2020 | 41 | 0.040 |
Why?
| | RNA-Binding Proteins | 1 | 2021 | 128 | 0.040 |
Why?
| | Trans-Activators | 1 | 2021 | 135 | 0.040 |
Why?
| | Genetic Association Studies | 1 | 2021 | 122 | 0.040 |
Why?
| | Communicable Disease Control | 1 | 2020 | 38 | 0.040 |
Why?
| | HEK293 Cells | 1 | 2021 | 229 | 0.040 |
Why?
| | Adaptation, Physiological | 1 | 2021 | 110 | 0.040 |
Why?
| | Mice, Inbred BALB C | 1 | 2021 | 312 | 0.040 |
Why?
| | Truth Disclosure | 1 | 2020 | 16 | 0.040 |
Why?
| | Survival Rate | 2 | 2015 | 945 | 0.040 |
Why?
| | Receptors, GABA-A | 1 | 2019 | 11 | 0.040 |
Why?
| | Up-Regulation | 1 | 2021 | 454 | 0.040 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2021 | 184 | 0.040 |
Why?
| | Epidemiologic Methods | 1 | 2019 | 46 | 0.040 |
Why?
| | History, 19th Century | 1 | 2019 | 23 | 0.040 |
Why?
| | Drug Resistance, Microbial | 1 | 2019 | 47 | 0.040 |
Why?
| | Forecasting | 1 | 2020 | 154 | 0.040 |
Why?
| | History, 21st Century | 1 | 2019 | 59 | 0.040 |
Why?
| | Immunity, Innate | 1 | 2020 | 117 | 0.040 |
Why?
| | History, 20th Century | 1 | 2019 | 96 | 0.040 |
Why?
| | Hematopoietic Stem Cells | 1 | 2021 | 187 | 0.040 |
Why?
| | Sensitivity and Specificity | 2 | 2013 | 891 | 0.040 |
Why?
| | Protein Binding | 1 | 2021 | 667 | 0.040 |
Why?
| | Oxidative Stress | 1 | 2024 | 807 | 0.040 |
Why?
| | Cell Line, Tumor | 1 | 2023 | 1470 | 0.040 |
Why?
| | Interprofessional Relations | 1 | 2020 | 90 | 0.040 |
Why?
| | Histones | 1 | 2021 | 314 | 0.040 |
Why?
| | Feasibility Studies | 1 | 2020 | 406 | 0.040 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2024 | 603 | 0.040 |
Why?
| | Tropical Climate | 1 | 2018 | 11 | 0.040 |
Why?
| | Japan | 1 | 2018 | 38 | 0.040 |
Why?
| | Combined Modality Therapy | 1 | 2020 | 639 | 0.040 |
Why?
| | Antigens, Viral | 1 | 2018 | 43 | 0.040 |
Why?
| | T-Lymphocytes | 1 | 2020 | 340 | 0.040 |
Why?
| | Case Management | 1 | 2018 | 43 | 0.040 |
Why?
| | Sputum | 1 | 2018 | 69 | 0.040 |
Why?
| | Etoposide | 1 | 2017 | 74 | 0.030 |
Why?
| | Public Health Surveillance | 1 | 2017 | 18 | 0.030 |
Why?
| | United States | 2 | 2021 | 5192 | 0.030 |
Why?
| | Computer Simulation | 1 | 2018 | 290 | 0.030 |
Why?
| | Erythroid Cells | 1 | 2017 | 5 | 0.030 |
Why?
| | Urban Population | 1 | 2018 | 162 | 0.030 |
Why?
| | Genes, Dominant | 1 | 2017 | 21 | 0.030 |
Why?
| | Erythropoiesis | 1 | 2017 | 18 | 0.030 |
Why?
| | Genes, X-Linked | 1 | 2017 | 7 | 0.030 |
Why?
| | Glucosephosphate Dehydrogenase | 1 | 2017 | 6 | 0.030 |
Why?
| | Gene Frequency | 1 | 2017 | 98 | 0.030 |
Why?
| | Health Personnel | 1 | 2020 | 256 | 0.030 |
Why?
| | Erythrocytes | 1 | 2017 | 84 | 0.030 |
Why?
| | Drug Combinations | 1 | 2017 | 132 | 0.030 |
Why?
| | Models, Genetic | 1 | 2017 | 169 | 0.030 |
Why?
| | Alkynes | 1 | 2016 | 6 | 0.030 |
Why?
| | Cyclopropanes | 1 | 2016 | 27 | 0.030 |
Why?
| | Bacterial Proteins | 2 | 2010 | 361 | 0.030 |
Why?
| | Blood-Brain Barrier | 1 | 2016 | 48 | 0.030 |
Why?
| | Protein-Tyrosine Kinases | 1 | 1996 | 87 | 0.030 |
Why?
| | Efficiency | 1 | 2016 | 32 | 0.030 |
Why?
| | Africa, Western | 1 | 2015 | 5 | 0.030 |
Why?
| | Quality-Adjusted Life Years | 1 | 2016 | 66 | 0.030 |
Why?
| | Disease Reservoirs | 1 | 2015 | 3 | 0.030 |
Why?
| | Access to Information | 1 | 2015 | 19 | 0.030 |
Why?
| | Gene Expression Regulation, Viral | 1 | 2015 | 49 | 0.030 |
Why?
| | Immunization Programs | 1 | 2015 | 23 | 0.030 |
Why?
| | Viral Hepatitis Vaccines | 1 | 2015 | 5 | 0.030 |
Why?
| | Basic Reproduction Number | 1 | 2015 | 1 | 0.030 |
Why?
| | Phylogeography | 1 | 2015 | 6 | 0.030 |
Why?
| | Health Priorities | 1 | 2015 | 19 | 0.030 |
Why?
| | Meteorological Concepts | 1 | 2015 | 2 | 0.030 |
Why?
| | Promoter Regions, Genetic | 1 | 2017 | 467 | 0.030 |
Why?
| | Protein Conformation | 1 | 2015 | 176 | 0.030 |
Why?
| | Diarrhea | 1 | 2015 | 95 | 0.030 |
Why?
| | Pharynx | 1 | 2015 | 31 | 0.030 |
Why?
| | Genome, Bacterial | 1 | 2015 | 58 | 0.030 |
Why?
| | Family Health | 1 | 2015 | 79 | 0.030 |
Why?
| | Cost-Benefit Analysis | 1 | 2016 | 267 | 0.030 |
Why?
| | Biological Assay | 1 | 2014 | 47 | 0.030 |
Why?
| | Immunoblotting | 1 | 2014 | 116 | 0.030 |
Why?
| | Gene Expression | 1 | 2017 | 618 | 0.030 |
Why?
| | Models, Molecular | 1 | 2015 | 348 | 0.030 |
Why?
| | Clinical Trials as Topic | 1 | 2017 | 467 | 0.030 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 235 | 0.030 |
Why?
| | Malawi | 1 | 2014 | 14 | 0.030 |
Why?
| | Child Health Services | 1 | 2015 | 79 | 0.030 |
Why?
| | Methylation | 1 | 2014 | 126 | 0.030 |
Why?
| | Epigenesis, Genetic | 1 | 2017 | 406 | 0.030 |
Why?
| | Placebos | 1 | 2013 | 85 | 0.030 |
Why?
| | Geography | 1 | 2014 | 65 | 0.030 |
Why?
| | Sequence Alignment | 1 | 2014 | 125 | 0.030 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 2013 | 66 | 0.030 |
Why?
| | Immunomodulation | 1 | 2013 | 38 | 0.030 |
Why?
| | Chromosomes, Human, Pair 5 | 1 | 2013 | 17 | 0.030 |
Why?
| | Cells, Cultured | 1 | 2017 | 1567 | 0.030 |
Why?
| | Killer Cells, Natural | 1 | 2013 | 116 | 0.030 |
Why?
| | Models, Statistical | 1 | 2014 | 230 | 0.030 |
Why?
| | Parents | 1 | 2016 | 335 | 0.020 |
Why?
| | Thalidomide | 1 | 2013 | 377 | 0.020 |
Why?
| | Virology | 1 | 2010 | 6 | 0.020 |
Why?
| | Coma | 1 | 2010 | 16 | 0.020 |
Why?
| | Antibodies, Monoclonal | 1 | 2014 | 481 | 0.020 |
Why?
| | Cryptococcus gattii | 1 | 2010 | 1 | 0.020 |
Why?
| | Flucytosine | 1 | 2010 | 13 | 0.020 |
Why?
| | Cytokines | 1 | 2013 | 623 | 0.020 |
Why?
| | DNA Gyrase | 1 | 2010 | 4 | 0.020 |
Why?
| | Immunoassay | 1 | 2010 | 23 | 0.020 |
Why?
| | High-Throughput Screening Assays | 1 | 2010 | 38 | 0.020 |
Why?
| | Algorithms | 1 | 2014 | 672 | 0.020 |
Why?
| | Amphotericin B | 1 | 2010 | 103 | 0.020 |
Why?
| | Carrier State | 1 | 2009 | 10 | 0.020 |
Why?
| | RNA, Viral | 1 | 2010 | 127 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2013 | 1229 | 0.020 |
Why?
| | Hospitalization | 1 | 2014 | 736 | 0.020 |
Why?
| | Alphavirus | 1 | 2008 | 1 | 0.020 |
Why?
| | Retroviridae | 1 | 2008 | 5 | 0.020 |
Why?
| | Culex | 1 | 2008 | 5 | 0.020 |
Why?
| | Disease-Free Survival | 1 | 2009 | 460 | 0.020 |
Why?
| | Anaerobiosis | 1 | 2008 | 20 | 0.020 |
Why?
| | Sequence Homology, Nucleic Acid | 1 | 2008 | 47 | 0.020 |
Why?
| | Transduction, Genetic | 1 | 2008 | 44 | 0.020 |
Why?
| | Gene Knockdown Techniques | 1 | 2008 | 108 | 0.020 |
Why?
| | Species Specificity | 1 | 2008 | 192 | 0.020 |
Why?
| | Gene Expression Regulation, Bacterial | 1 | 2009 | 187 | 0.020 |
Why?
| | Pregnancy | 1 | 2015 | 2680 | 0.020 |
Why?
| | Ankyrin Repeat | 1 | 2007 | 3 | 0.020 |
Why?
| | Antifungal Agents | 1 | 2010 | 347 | 0.020 |
Why?
| | Mice, Mutant Strains | 1 | 2007 | 70 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2015 | 3392 | 0.020 |
Why?
| | Signal Transduction | 1 | 2014 | 1671 | 0.020 |
Why?
| | Birds | 1 | 2007 | 14 | 0.020 |
Why?
| | Fibroblasts | 1 | 2008 | 355 | 0.020 |
Why?
| | Program Development | 1 | 2007 | 165 | 0.020 |
Why?
| | Absorption | 1 | 2005 | 22 | 0.020 |
Why?
| | Polymorphism, Genetic | 1 | 2006 | 185 | 0.020 |
Why?
| | Administration, Topical | 1 | 2005 | 61 | 0.020 |
Why?
| | Oxygen | 1 | 2008 | 336 | 0.020 |
Why?
| | Bone Marrow Transplantation | 1 | 2005 | 113 | 0.010 |
Why?
| | Skin Diseases | 1 | 2005 | 115 | 0.010 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2007 | 857 | 0.010 |
Why?
|
|
Farrar's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|